Buy-And-Bill A Bust For Novartis's Leqvio?
The US commercial strategy for the PCSK9 inhibitor Leqvio was tied to reimbursement under Medicare Part B, but it hasn't developed the way Novartis envisioned.
You may also be interested in...
Lilly's Mounjaro and Roche's Vabysmo appear on track to be fast blockbusters in a year that saw the fewest drug launches since 2016.
A mixed sales bag for the Swiss major in Q3 saw a strong start for Pluvicto dampened by a reverse for Zolgensma, weak growth for Cosentyx and continued sluggishness for Leqvio. Positive data for potential blockbuster iptacopan were another bright spot, as Novartis prioritizes the delivery of high value medicines, and concentrates on the US market.
Regeneron antitrust suit alleges Amgen’s bundling of Repatha rebates with Otezla and Enbrel has restricted Praluent’s market access and ability to compete with Repatha.